Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Arrowhead Pharmaceuticals recently reported interim Phase 1/2a data showing its RNAi obesity candidates ARO-INHBE and ARO-ALK7 reduced visceral and liver fat and enhanced weight loss versus ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the ...

This means that siRNA demonstrates significant potential for therapeutic use, given its capacity to control protein levels. However, one of the main drawbacks with siRNA is that researchers have had ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...